We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Synchrotron Sheds Light on Possible Anticancer Target

By LabMedica International staff writers
Posted on 27 Aug 2008
Cancer researchers have taken advantage of the resolving power of the Diamond Light Synchrotron (United Kingdom) to solve the three-dimensional structure of Mps-1, a protein that regulates the number of chromosomes during cell division and thereby plays an essential role in the prevention of cancer.

The Diamond Light Synchrotron is a third generation, medium energy source, with electron beam energies of 3 GeV. More...
Specially designed arrays of magnets, called insertion devices, produce exceptionally bright light beams to suit a huge variety of complex experiments. At the heart of the synchrotron is a storage ring: a huge, doughnut-shaped vacuum chamber. Electrons are accelerated by the linear accelerator and the booster synchrotron, and confined to travel around the storage ring at nearly the speed of light. Because the electrons are constantly changing direction, they are accelerating, and accelerating electrons lose energy in the form of synchrotron light.

In the current study, published in the August 1, 2008, edition of the Journal of Biological Chemistry (JBC), investigators at the University of Manchester (United Kingdom) used the Diamond Light Synchrotron to determine the X-ray structure of Mps1, both alone and in complex with the ATP competitive inhibitor SP600125.

Mps1 adopted a classic protein kinase fold, with the inhibitor sitting in the ATP-binding site where it was stabilized by hydrophobic interactions. In addition, they identified a secondary pocket, not utilized by SP600125, which might be exploited for the rational design of specific Mps1 inhibitors. These structures provide important insights into the interaction of this protein kinase with small molecules and suggest potential mechanisms for Mps1 regulation.

Co-senior author Dr. Patrick Eyers, professor of pharmaceutical sciences at the University of Manchester, explained, "Mps1 is a rational target because of its critical role in preventing aneuploidy. We wanted to see what this protein looked like at the molecular level and, by revealing the active site ‘lock' help design a new inhibitory ‘key' to physically block the ATP-binding site. The crystallographic structures of only a few key ‘mitotic' kinases are currently known so we are very early in the game. The scientific community has high hopes for developing novel ‘anti-mitotic' cancer therapies using this method of structure-based drug design.”

Related Links:
University of Manchester
Diamond Light Synchrotron


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Procalcitonin Test
LIAISON B•R•A•H•M•S PCT II GEN
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.